Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2025 AML Highlights
22 January 2026 | Virtual Webinar
Post-ASH 2025 AML Highlights
Featuring presentations & discussions on selected AML abstracts from the 67th ASH Annual Meeting and Exposition
Thursday 22 January | 09:00 – 11:00 CST/ 15:00 – 17:00 GMT/ 16:00 – 18:00 CET
Chair: Charles Craddock | Moderators: Courtney DiNardo, Naval Daver, and Jessica Altman
The Post-ASH 2025 AML Highlights has been supported by Johnson & Johnson (Silver Sponsor), Kura Oncology (Silver Sponsor) and Sumitomo Pharma (Silver Sponsor). Supporters have no influence over the production of content.
Explore the presentations and discussions below:
Session 1: Novel approaches to conditioning in AML
Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: a Phase II trial
Uday Popat The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Addition of thiotepa to a busulphan-based conditioning regimen does not improve survival in patients allografted for AML and MDS: results of the UK Impact COSI trial
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Session 2: Latest with venetoclax-based therapy in newly-diagnosed AML
Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated AML
Roberta Santos Azevedo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Signaling mutations negate the favorable impact of NPM1 in older patients with newly diagnosed AML treated with ven/HMA
Fieke Hoff UT Southwestern Medical Center, Dallas, TX, United States
Phase II PARADIGM study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with AML
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
Prognostic risk integration for survival modeling (PRISM) in newly diagnosed AML treated with venetoclax: a multinational retrospective cohort study
Curtis Lachowiez University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel Discussion
Session 3: Advances with I-O therapies in AML
Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed AML
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Correlative data from an ongoing Phase I, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK-cell therapy for AML
Muharrem Muftuoglu The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Preliminary anti-leukemia activity from a Phase I study of CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in R/R AML and MDS
Maher Abdul-Hay NYU Langone, New York City, NY, United States
Session 4: Recent progress with menin inhibitors in AML
Revumenib for patients with R/R KMT2Ar acute leukemia: outcomes by leukemia type in the Phase II AUGMENT-101 study
Ibrahim Aldoss City of Hope, Duarte, CA, United States
Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m AML: Phase Ib results from KOMET-007
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Ziftomenib in combination with venetoclax and azacitidine in R/R NPM1-m or KMT2A-r AML: updated Phase Ia/b safety and clinical activity results from KOMET-007
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Phase III Camelot-2 study: bleximenib, venetoclax and azacitidine for patients with newly diagnosed AML harboring KMT2A rearrangements or NPM1 mutations, ineligible for intensive chemotherapy
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Monotherapy update from Phase I portion in Phase I/II trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with R/R acute leukemia
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel Discussion
